Nyxoah S A (NYXH) Stock Price, Quote & News

Company Profile

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 32 1 022 23 55

Fax: 32 1 045 90 75

Website: www.nyxoah.com

Address:

Rue Edouard Belin 12, Mont-Saint-Guibert, Belgium

Muddymac Jul. 16 at 5:02 PM

$NYXH Should hopefully get FDA approval before August. Let’s go.

0 · Reply

coletrain89 Jul. 15 at 2:09 AM

$NYXH tick tock on the clock is painful

0 · Reply

Frankie95 Jul. 11 at 1:34 PM

$NYXH never seen a company with less interest in their investors. zero updates ever.

0 · Reply

coletrain89 Jul. 7 at 12:42 PM

$NYXH maybe news this week

0 · Reply

TheGodsMustBeCrazy Jul. 7 at 12:09 AM

$NYXH This month

0 · Reply

coletrain89 Jun. 28 at 7:19 PM

$NYXH what’s up fam . Just stumbled into this room. Does anybody know where the front desk is to check in for the rocket launch ? 🚀

0 · Reply

TheGodsMustBeCrazy Jun. 25 at 2:09 AM

$NYXH over the next few months they probably get fda approval. stock likely doubles or more on that news.

0 · Reply

sem18 Jun. 17 at 10:54 AM

$NYXH Immuneering Corporation (IMRX) announced it will host a conference call and webcast on June 17, 2025, at 8:00 am ET to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The webcast will be available live and archived in the company's Investor Relations section on their website. Immuneering, a clinical-stage oncology company, focuses on developing treatments to help cancer patients outlive their disease.

0 · Reply

TheGodsMustBeCrazy Jun. 17 at 12:04 AM

$NYXH If they get FDA approval in the next 30-90 days, which is very likely, this should be worth at least $1B (INSPIRE has a several billion dollar market cap and is an inferior product), ie 26.7/share. That's ~345% the current price.

1 · Reply

TheGodsMustBeCrazy Jun. 12 at 6:57 PM

$NYXH

0 · Reply

Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 2, 2025

May 28, 2025, 4:30 PM EDT - 7 weeks ago

Nyxoah to Present at the Jefferies Global Healthcare Conference

May 14, 2025, 2:35 PM EDT - 2 months ago

Nyxoah SA (NYXH) Q1 2025 Earnings Call Transcript

May 14, 2025, 1:00 AM EDT - 2 months ago

Nyxoah Reports First Quarter Financial and Operating Results

May 9, 2025, 4:30 PM EDT - 2 months ago

Publication relating to transparency notifications

May 9, 2025, 1:00 AM EDT - 2 months ago

Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 11, 2025

Apr 22, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nyxoah S.A. (NYXH) And Encourages Shareholders to Reach Out

Apr 21, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Shareholders to Learn More About the Investigation

Apr 20, 2025, 10:00 AM EDT - 3 months ago

Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 18, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Shareholders to Inquire about Securities Investigation

Apr 17, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Investors to Connect

Apr 16, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Stockholders to Inquire about Securities Investigation

Apr 16, 2025, 2:00 AM EDT - 3 months ago

Conditional Issuance of Shares

Apr 15, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Investors to Learn More About the Investigation

Apr 14, 2025, 10:00 AM EDT - 3 months ago

Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 11, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Stockholders to Connect

Apr 10, 2025, 10:00 AM EDT - 3 months ago

Nyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 9, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Stockholders to Learn More About the Investigation

Apr 8, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Investors to Inquire about Securities Investigation

Apr 8, 2025, 1:00 AM EDT - 3 months ago

Nyxoah Provides Update on FDA Approvable Letter for Genio System

Apr 7, 2025, 3:00 PM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nyxoah S.A. (NYXH) And Encourages Investors to Reach Out

Apr 7, 2025, 9:33 AM EDT - 3 months ago

NYXH Investors Have Opportunity to Join Nyxoah S.A. Fraud Investigation with the Schall Law Firm

Mar 31, 2025, 5:40 PM EDT - 3 months ago

Nyxoah S.A. Investors: Company Investigated by the Portnoy Law Firm

Mar 31, 2025, 2:45 PM EDT - 3 months ago

Nyxoah S.A. Being Investigated on Behalf of Nyxoah S.A.

Mar 26, 2025, 3:00 AM EDT - 4 months ago

FDA Issues Nyxoah an Approvable Letter for its Genio® System

Mar 13, 2025, 4:45 PM EDT - 4 months ago

Nyxoah SA (NYXH) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 2:00 AM EDT - 4 months ago

Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results

Mar 10, 2025, 5:05 PM EDT - 4 months ago

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025

Mar 3, 2025, 4:30 PM EST - 4 months ago

Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

Feb 19, 2025, 1:05 AM EST - 5 months ago

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East

Dec 30, 2024, 4:01 AM EST - 7 months ago

Nyxoah: The Future Of OSA

Dec 13, 2024, 2:05 AM EST - 7 months ago

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

Nov 20, 2024, 4:05 PM EST - 8 months ago

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 1:00 AM EST - 8 months ago

Invitation to attend the special shareholders' meeting of the Company to be held on December 19, 2024

Nov 8, 2024, 6:46 PM EST - 8 months ago

Nyxoah S.A. (NYXH) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:45 PM EST - 9 months ago

Nyxoah Appoints John Landry as Chief Financial Officer

Oct 22, 2024, 4:30 PM EDT - 9 months ago

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024

Oct 7, 2024, 5:00 PM EDT - 10 months ago

Nyxoah Raises $27 Million through its At-the-Market Offering

Sep 27, 2024, 4:30 PM EDT - 10 months ago

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update

Sep 5, 2024, 4:30 PM EDT - 11 months ago

Nyxoah to Participate in Upcoming Investor Conferences

Sep 2, 2024, 4:05 PM EDT - 11 months ago

Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device

Aug 11, 2024, 1:44 AM EDT - 1 year ago

Nyxoah S.A. (NYXH) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results

Jul 29, 2024, 4:30 PM EDT - 1 year ago

Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024

Jul 15, 2024, 2:00 AM EDT - 1 year ago

Nyxoah Appoints Scott Holstine as Chief Commercial Officer

Muddymac Jul. 16 at 5:02 PM

$NYXH Should hopefully get FDA approval before August. Let’s go.

0 · Reply

coletrain89 Jul. 15 at 2:09 AM

$NYXH tick tock on the clock is painful

0 · Reply

Frankie95 Jul. 11 at 1:34 PM

$NYXH never seen a company with less interest in their investors. zero updates ever.

0 · Reply

coletrain89 Jul. 7 at 12:42 PM

$NYXH maybe news this week

0 · Reply

TheGodsMustBeCrazy Jul. 7 at 12:09 AM

$NYXH This month

0 · Reply

coletrain89 Jun. 28 at 7:19 PM

$NYXH what’s up fam . Just stumbled into this room. Does anybody know where the front desk is to check in for the rocket launch ? 🚀

0 · Reply

TheGodsMustBeCrazy Jun. 25 at 2:09 AM

$NYXH over the next few months they probably get fda approval. stock likely doubles or more on that news.

0 · Reply

sem18 Jun. 17 at 10:54 AM

0 · Reply

TheGodsMustBeCrazy Jun. 17 at 12:04 AM

1 · Reply

TheGodsMustBeCrazy Jun. 12 at 6:57 PM

$NYXH

0 · Reply

Shinji_Okamura Jun. 6 at 6:13 AM

$NYXH alert ! https://dockets.justia.com/docket/delaware/dedce/1:2025cv00667/89290

2 · Reply

Culby Jun. 5 at 1:54 PM

$NYXH are the market makers pushing this down to grab more shares because they know approval is coming in the next few days?

4 · Reply

Frankie95 Jun. 5 at 10:06 AM

$NYXH wtf

0 · Reply

Frankie95 Jun. 4 at 2:15 PM

FDA approval should be any day. could see this hitting 12-13$.

1 · Reply

POLPOLP Jun. 3 at 8:43 PM

$NYXH

0 · Reply

TheGodsMustBeCrazy Jun. 2 at 5:32 AM

$NYXH

1 · Reply

healthcareguru May. 28 at 2:21 PM

$INSP this is likely to blowup on $NYXH approval imminently… Then you have GLP-1 on-label headwinds for the next year+ before annualizing. Not a good setup.

2 · Reply